2015-09-14 21:49:48 UTC

GI and Liver Diseases are a Substantial Burden and Cost in the US

Sept. 15, 2015

New Gastro research provides up-to-date statistics on the prevalence of GI, liver and pancreatic diseases.

An article published in Gastroenterology as an epub ahead of print provides a complete and accurate report on the current state of morbidity, mortality and cost associated with GI, liver and pancreatic diseases in the U.S. 

Anne F. Peery, MD, MSCR, and colleagues from University of North Carolina, Chapel Hill, report that:

  • There were 7 million diagnoses of GERD and almost 4 million diagnoses of hemorrhoids in the ambulatory setting in a year.
  • Functional and motility disorders resulted in nearly 1 million emergency department visits in 2012; most of these visits were for constipation.
  • GI hemorrhage was the most common diagnosis leading to hospitalization, with more than 500,000 discharges in 2012 at a cost of nearly $5 billion dollars.
  • Hospitalizations and associated charges for IBD, Clostridium difficile infection and chronic liver disease have increased over the last 20 years.
  • In 2011, there were more than 1 million people in the U.S. living with colorectal cancer.
  • The leading GI cause of death was colorectal cancer, followed by pancreatic and hepatobiliary neoplasms.

For this analysis, Dr. Peery and colleagues gathered data from national databases on health-care utilization in the ambulatory and inpatient setting along with data on cancers and mortality from 2007 through 2012. The most recent data were obtained from CDC, AHRQ and NCI. 

These statistics quantifying the burden of GI and liver diseases are valuable for researchers, clinicians, policy makers and public-health professionals. Review the full study on Gastroenterology (login required) to understand additional trends highlighted by this comprehensive data review.

More on Clostridium difficile infection

How to Select the Best FMT Donor

Oct. 25, 2017

Dr. Gail Hecht debunks the myth that a patient’s family or friend is the best donor for a fecal microbiota transplantation.

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Study Finds C. Diff Infections on the Rise, FMT Most Promising Treatment

July 5, 2017

AGA is tracking outcomes of fecal microbiota transplantation through an observational registry.